IP waiver will not boost vaccine production: OPPI
The Hindu
‘Critical know-how key to scaling up’
The Organisation of Pharmaceutical Producers of India (OPPI) on Monday said waiving intellectual property rights will not lead to increased production of COVID-19 vaccines, as it is not the barrier to their adequate availability in India. A proposal moved by India and South Africa before the World Trade Organisation (WTO) to temporarily suspend trade-related aspects of intellectual property rights for the COVID-19 vaccines to increase their access amid the pandemic has gained support across a number of countries, including the U.S. Vaccine manufacturing is a complex process and scaling up capacities involves the transfer of critical know-how, it added.More Related News

Scaling Artificial Intelligence(AI) at the speed at which consultants project is not possible by the laws of physics and may not be environmentally sustainable, said Tanvir Khan, who is the Executive Vice President and Chief Operating Officer of NTT DATA North America, part of the Japanese technology services and data centre company NTT Data, in an interview with The Hindu.












